{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:03:59Z","timestamp":1790352239426,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01598-5","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:40:41Z","timestamp":1790350841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative Circulating Tumor DNA in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma: Molecular Residual Disease, Recurrence Prediction, and a Trial-Ready Framework for Treatment Adaptation"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4795","authenticated-orcid":false,"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"1598_CR1","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1.","journal-title":"Lancet"},{"key":"1598_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393:217\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2503701.","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"1598_CR3","doi-asserted-by":"publisher","first-page":"abstractLBA81","DOI":"10.1016\/j.annonc.2025.09.096","volume":"36","author":"J Tabernero","year":"2025","unstructured":"Tabernero J, Al-Batran SE, Wainberg ZAA, Muro K, Molena D, Van Cutsem E, et al. Final overall survival and the association of pathological outcomes with event-free survival in MATTERHORN: a randomised, phase III study of durvalumab plus fluorouracil, leucovorin, oxaliplatin and docetaxel in resectable gastric\/gastroesophageal junction adenocarcinoma. Ann Oncol. 2025;36(Suppl):abstractLBA81. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.096.","journal-title":"Ann Oncol"},{"key":"1598_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25:212\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(23)00541-7.","journal-title":"Lancet Oncol"},{"key":"1598_CR5","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO-25-00486","volume":"43","author":"K Shitara","year":"2025","unstructured":"Shitara K, Rha SY, Wyrwicz L, Oshima T, Karaseva N, Osipov M, et al. Pembrolizumab plus chemotherapy versus chemotherapy as perioperative therapy in locally advanced gastric and gastroesophageal junction cancer: final analysis of the randomized, phase III KEYNOTE-585 study. J Clin Oncol. 2025;43:3152\u20139. https:\/\/doi.org\/10.1200\/JCO-25-00486.","journal-title":"J Clin Oncol"},{"key":"1598_CR6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41591-023-02758-x","volume":"30","author":"YL Verschoor","year":"2024","unstructured":"Verschoor YL, van de Haar J, van den Berg JG, van Sandick JW, Kodach LL, van Dieren JM, et al. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial. Nat Med. 2024;30:519\u201330. https:\/\/doi.org\/10.1038\/s41591-023-02758-x.","journal-title":"Nat Med"},{"key":"1598_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24. https:\/\/doi.org\/10.1126\/scitranslmed.3007094.","journal-title":"Sci Transl Med"},{"key":"1598_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","volume":"16","author":"K Pantel","year":"2019","unstructured":"Pantel K, Alix-Panabieres C. Liquid biopsy and minimal residual disease-latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16:409\u201324. https:\/\/doi.org\/10.1038\/s41571-019-0187-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"1598_CR9","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022;33:750\u201368. https:\/\/doi.org\/10.1016\/j.annonc.2022.05.520.","journal-title":"Ann Oncol"},{"key":"1598_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10147-024-02683-0","volume":"30","author":"S Kobayashi","year":"2025","unstructured":"Kobayashi S, Nakamura Y, Hashimoto T, Bando H, Oki E, Karasaki T, et al. Japan Society of Clinical Oncology position paper on appropriate clinical use of molecular residual disease testing. Int J Clin Oncol. 2025;30:605\u201354. https:\/\/doi.org\/10.1007\/s10147-024-02683-0.","journal-title":"Int J Clin Oncol"},{"key":"1598_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2531-z","volume":"11","author":"J Yang","year":"2020","unstructured":"Yang J, Gong Y, Lam VK, Shi Y, Guan Y, Zhang Y, et al. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death Dis. 2020;11:346. https:\/\/doi.org\/10.1038\/s41419-020-2531-z.","journal-title":"Cell Death Dis"},{"key":"1598_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14310-3","volume":"11","author":"A Leal","year":"2020","unstructured":"Leal A, van Grieken NCT, Palsgrove DN, Phallen J, Medina JE, Hruban C, et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun. 2020;11:525. https:\/\/doi.org\/10.1038\/s41467-020-14310-3.","journal-title":"Nat Commun"},{"key":"1598_CR13","doi-asserted-by":"publisher","first-page":"e2200420","DOI":"10.1200\/PO.22.00420","volume":"6","author":"BM Huffman","year":"2022","unstructured":"Huffman BM, Aushev VN, Budde GL, Chao J, Dayyani F, Hanna D, et al. Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers. JCO Precis Oncol. 2022;6:e2200420. https:\/\/doi.org\/10.1200\/PO.22.00420.","journal-title":"JCO Precis Oncol"},{"key":"1598_CR14","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/1878-0261.13481","volume":"17","author":"M Zhang","year":"2023","unstructured":"Zhang M, Yang H, Fu T, Meng M, Feng Y, Qu C, et al. Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II\/III gastric cancer. Mol Oncol. 2023;17:1930\u201342. https:\/\/doi.org\/10.1002\/1878-0261.13481.","journal-title":"Mol Oncol"},{"key":"1598_CR15","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/cac2.12494","volume":"43","author":"SQ Yuan","year":"2023","unstructured":"Yuan SQ, Nie RC, Huang YS, Chen YB, Wang SY, Sun XW, et al. Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer. Cancer Commun. 2023;43:1312\u201325. https:\/\/doi.org\/10.1002\/cac2.12494.","journal-title":"Cancer Commun"},{"key":"1598_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10120-024-01556-9","volume":"28","author":"CR Iden","year":"2025","unstructured":"Iden CR, Mustafa SM, Ogaard N, Henriksen T, Jensen SO, Ahlborn LB, et al. Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer. Gastric Cancer. 2025;28:83\u201395. https:\/\/doi.org\/10.1007\/s10120-024-01556-9.","journal-title":"Gastric Cancer"},{"key":"1598_CR17","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1038\/s41467-025-62056-7","volume":"16","author":"A Zaanan","year":"2025","unstructured":"Zaanan A, Didelot A, Broudin C, Laliotis G, Spickard E, Dutta P, et al. Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study. Nat Commun. 2025;16:6815. https:\/\/doi.org\/10.1038\/s41467-025-62056-7.","journal-title":"Nat Commun"},{"key":"1598_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70065","volume":"6","author":"Z Liu","year":"2025","unstructured":"Liu Z, Shi Z, Jiang W, Shen Z, Chen W, Shen K, et al. Circulating tumor DNA analysis for prediction of prognosis and molecular insights in patients with resectable gastric cancer: results from a prospective study. MedComm. 2025;6:e70065. https:\/\/doi.org\/10.1002\/mco2.70065.","journal-title":"MedComm"},{"issue":"16suppl","key":"1598_CR19","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1200\/JCO.2026.44.16_suppl.4081","volume":"44","author":"E Bando","year":"2026","unstructured":"Bando E, Yura M, Koseki Y, Yasufuku I, Makiyama A, Misawa K, et al. Whole-genome sequencing-based ultra-sensitive ctDNA molecular residual disease assessment in resectable gastric cancer: results from MONSTAR-SCREEN-3. J Clin Oncol. 2026;44(16suppl):4081. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.4081.","journal-title":"J Clin Oncol"},{"key":"1598_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1774979","volume":"16","author":"J Bian","year":"2026","unstructured":"Bian J, Liu J. Circulating tumor DNA and prognosis in gastric cancer patients undergoing surgery: meta-analysis and trial sequential analysis. Front Oncol. 2026;16:1774979. https:\/\/doi.org\/10.3389\/fonc.2026.1774979.","journal-title":"Front Oncol"},{"key":"1598_CR21","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41416-020-1002-8","volume":"123","author":"MR Openshaw","year":"2020","unstructured":"Openshaw MR, Suwaidan AA, Ottolini B, Fernandez-Garcia D, Richards CJ, Page K, et al. Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma. Br J Cancer. 2020;123:1271\u20139. https:\/\/doi.org\/10.1038\/s41416-020-1002-8.","journal-title":"Br J Cancer"},{"key":"1598_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10102108","volume":"10","author":"CG Lengyel","year":"2021","unstructured":"Lengyel CG, Hussain S, Trapani D, El Bairi K, Altuna SC, Seeber A, et al. The emerging role of liquid biopsy in gastric cancer. J Clin Med. 2021;10:2108. https:\/\/doi.org\/10.3390\/jcm10102108.","journal-title":"J Clin Med"},{"key":"1598_CR23","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.3390\/cancers14205105","volume":"14","author":"J Mencel","year":"2022","unstructured":"Mencel J, Slater S, Cartwright E, Starling N. The role of circulating tumor DNA in gastric cancer. Cancers (Basel). 2022;14:5105. https:\/\/doi.org\/10.3390\/cancers14205105.","journal-title":"Cancers (Basel)"},{"key":"1598_CR24","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/s41388-024-03034-z","volume":"43","author":"K van der Sluis","year":"2024","unstructured":"van der Sluis K, van Sandick JW, Vollebergh MA, van Dieren JM, Hugen N, Hartemink KJ, et al. Improving diagnostic accuracy of identifying gastric cancer patients with peritoneal metastases: tumor-guided cell-free DNA analysis of peritoneal fluid. Oncogene. 2024;43:1877\u201382. https:\/\/doi.org\/10.1038\/s41388-024-03034-z.","journal-title":"Oncogene"},{"key":"1598_CR25","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.21873\/anticanres.16367","volume":"43","author":"N Yukawa","year":"2023","unstructured":"Yukawa N, Yamada T, Aoyama T, Woo T, Ueda K, Mastuda A, et al. Tumor DNA in peritoneal lavage as a novel biomarker for predicting peritoneal recurrence in patients with gastric cancer. Anticancer Res. 2023;43:2069\u201376. https:\/\/doi.org\/10.21873\/anticanres.16367.","journal-title":"Anticancer Res"},{"key":"1598_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00546","volume":"8","author":"Z Allan","year":"2024","unstructured":"Allan Z, Witts S, Wong DJ, Liu DSH. Peritoneal tumor DNA as a prognostic biomarker in gastric cancer: a systematic review and meta-analysis. JCO Precis Oncol. 2024;8:e2300546. https:\/\/doi.org\/10.1200\/PO.23.00546.","journal-title":"JCO Precis Oncol"},{"key":"1598_CR27","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3969\/j.issn.1674-8115.2023.12.011","volume":"43","author":"L Bai","year":"2023","unstructured":"Bai L, Xia X, Cao H, Zhang Z. Progress in application of peritoneal lavage fluid circulating tumor DNA to predicting peritoneal metastasis of gastrointestinal cancer. J Shanghai Jiao Tong Univ (Med Sci). 2023;43:1554\u201361. https:\/\/doi.org\/10.3969\/j.issn.1674-8115.2023.12.011.","journal-title":"J Shanghai Jiao Tong Univ (Med Sci)"},{"key":"1598_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5230\/jgc.2024.24.e5","volume":"24","author":"HS Han","year":"2024","unstructured":"Han HS, Lee KW. Liquid biopsy: an emerging diagnostic, prognostic, and predictive tool in gastric cancer. J Gastric Cancer. 2024;24:4\u201328. https:\/\/doi.org\/10.5230\/jgc.2024.24.e5.","journal-title":"J Gastric Cancer"},{"key":"1598_CR29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202\u20139. https:\/\/doi.org\/10.1038\/nature13480.","journal-title":"Nature"},{"key":"1598_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449\u201356. https:\/\/doi.org\/10.1038\/nm.3850.","journal-title":"Nat Med"},{"key":"1598_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andre","year":"2023","unstructured":"Andre T, Tougeron D, Piessen G, de la Fouchardiere C, Louvet C, Adenis A, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol. 2023;41:255\u201365. https:\/\/doi.org\/10.1200\/JCO.22.00686.","journal-title":"J Clin Oncol"},{"key":"1598_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.annonc.2024.11.016","volume":"36","author":"A Raimondi","year":"2025","unstructured":"Raimondi A, Lonardi S, Murgioni S, Cardellino GG, Tamberi S, Strippoli A, et al. Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO. Ann Oncol. 2025;36:285\u201396. https:\/\/doi.org\/10.1016\/j.annonc.2024.11.016.","journal-title":"Ann Oncol"},{"key":"1598_CR33","doi-asserted-by":"publisher","first-page":"e000705","DOI":"10.1136\/jitc-2020-000705","volume":"8","author":"T Xie","year":"2020","unstructured":"Xie T, Zhang Z, Zhang X, Qi C, Shen L, Peng Z. Positive status of Epstein-Barr virus as a biomarker for gastric cancer immunotherapy: a prospective observational study. J Immunother Cancer. 2020;8:e000705. https:\/\/doi.org\/10.1136\/jitc-2020-000705.","journal-title":"J Immunother Cancer"},{"key":"1598_CR34","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1158\/2159-8290.CD-21-0687","volume":"12","author":"V Kumar","year":"2022","unstructured":"Kumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, et al. Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer. Cancer Discov. 2022;12:670\u201391. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0687.","journal-title":"Cancer Discov"},{"key":"1598_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023;29:127\u201334. https:\/\/doi.org\/10.1038\/s41591-022-02115-4.","journal-title":"Nat Med"},{"key":"1598_CR36","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, et al. CtDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med. 2024;30:3272\u201383. https:\/\/doi.org\/10.1038\/s41591-024-03254-6.","journal-title":"Nat Med"},{"key":"1598_CR37","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-026-04428-0","volume":"32","author":"H Bando","year":"2026","unstructured":"Bando H, Watanabe J, Takahashi Y, Kotaka M, Matsuhashi N, Oki E, et al. Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial. Nat Med. 2026;32:2473\u201380. https:\/\/doi.org\/10.1038\/s41591-026-04428-0.","journal-title":"Nat Med"},{"key":"1598_CR38","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386:2261\u201372. https:\/\/doi.org\/10.1056\/NEJMoa2200075.","journal-title":"N Engl J Med"},{"key":"1598_CR39","doi-asserted-by":"publisher","first-page":"S1687","DOI":"10.1016\/j.annonc.2025.09.038","volume":"36","author":"J Tie","year":"2025","unstructured":"Tie J, Wang Y, Loree JM, Cohen JD, Espinoza D, Wong R, et al. ctDNA-guided adjuvant chemotherapy de-escalation in stage III colon cancer: primary analysis of the ctDNA-negative cohort from the randomized AGITG DYNAMIC-III trial. Ann Oncol. 2025;36:S1687. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.038.","journal-title":"Ann Oncol"},{"key":"1598_CR40","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1038\/s41591-025-04030-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie J, Wang Y, Loree JM, Cohen JD, Wong R, Price T, et al. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial. Nat Med. 2025;31:4291\u2013300. https:\/\/doi.org\/10.1038\/s41591-025-04030-w.","journal-title":"Nat Med"},{"issue":"Suppl 2","key":"1598_CR41","doi-asserted-by":"publisher","first-page":"abstract723O","DOI":"10.1016\/j.annonc.2025.08.1298","volume":"36","author":"S Marsoni","year":"2025","unstructured":"Marsoni S, Prisciandaro M, Tarazona Llavero N, Montagut Viladot C, Sartore Bianchi A, Zampino MG, et al. Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: final results of the PEGASUS trial. Ann Oncol. 2025;36(Suppl 2):abstract723O. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.1298.","journal-title":"Ann Oncol"},{"key":"1598_CR42","doi-asserted-by":"publisher","first-page":"100114","DOI":"10.1016\/j.esmogo.2024.100114","volume":"6","author":"E Smyth","year":"2024","unstructured":"Smyth E, Griffiths D, Cozens K, Ewings S, Waugh R, Turkington RC, et al. Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER. ESMO Gastrointest Oncol. 2024;6:100114. https:\/\/doi.org\/10.1016\/j.esmogo.2024.100114.","journal-title":"ESMO Gastrointest Oncol"},{"key":"1598_CR43","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1111\/cas.14926","volume":"112","author":"H Taniguchi","year":"2021","unstructured":"Taniguchi H, Nakamura Y, Kotani D, Yukami H, Mishima S, Bando H, et al. Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer: CIRCULATE-Japan. Cancer Sci. 2021;112:2915\u201320. https:\/\/doi.org\/10.1111\/cas.14926.","journal-title":"Cancer Sci"},{"key":"1598_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc4308","volume":"6","author":"S Avanzini","year":"2020","unstructured":"Avanzini S, Kurtz DM, Chabon JJ, Moding EJ, Hori SS, Gambhir SS, et al. A mathematical model of ctDNA shedding predicts tumor detection size. Sci Adv. 2020;6:eabc4308. https:\/\/doi.org\/10.1126\/sciadv.abc4308.","journal-title":"Sci Adv"},{"key":"1598_CR45","doi-asserted-by":"publisher","first-page":"12484","DOI":"10.1038\/ncomms12484","volume":"7","author":"AL Young","year":"2016","unstructured":"Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016;7:12484. https:\/\/doi.org\/10.1038\/ncomms12484.","journal-title":"Nat Commun"},{"key":"1598_CR46","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","volume":"25","author":"P Razavi","year":"2019","unstructured":"Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25:1928\u201337. https:\/\/doi.org\/10.1038\/s41591-019-0652-7.","journal-title":"Nat Med"},{"key":"1598_CR47","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446\u201351. https:\/\/doi.org\/10.1038\/nature22364.","journal-title":"Nature"},{"key":"1598_CR48","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","volume":"7","author":"AA Chaudhuri","year":"2017","unstructured":"Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7:1394\u2013403. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0716.","journal-title":"Cancer Discov"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01598-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01598-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01598-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:40:42Z","timestamp":1790350842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01598-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1598"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01598-5","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"27 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Large language model assistance was used during drafting and language refinement. The authors critically reviewed, edited, verified the scientific content and references, and take full responsibility for the final manuscript.","order":4,"name":"Ethics","label":"Use of Artificial Intelligence Tools","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"226"}}